Intellia Therapeutics, Inc
NTLA Real Time Price USDRecent trades of NTLA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by NTLA's directors and management
Government lobbying spending instances
-
$30,000 Jan 19, 2022 Issue: Health Issues
-
$30,000 Oct 20, 2021 Issue: Health Issues
-
$30,000 Jul 18, 2021 Issue: Health Issues
-
$30,000 Apr 19, 2021 Issue: Health Issues
-
$50,000 Jan 20, 2021 Issue: Health Issues
-
$50,000 Oct 18, 2020 Issue: Health Issues
-
$50,000 Jul 19, 2020 Issue: Health Issues
-
$50,000 Apr 19, 2020 Issue: Health Issues
-
$50,000 Jan 20, 2020 Issue: Health Issues
-
$20,000 Oct 20, 2019 Issue: Health Issues
-
$15,000 Jul 01, 2019 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$15,000 Apr 03, 2019 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$15,000 Jan 15, 2019 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$15,000 Jul 03, 2018 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$15,000 Apr 17, 2018 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$15,000 Jan 11, 2018 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$15,000 Oct 28, 2017 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$15,000 Jun 30, 2017 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$15,000 Apr 14, 2017 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$15,000 Jan 05, 2017 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$15,000 Apr 07, 2016 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$15,000 Jan 07, 2016 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$15,000 Oct 13, 2015 Issue: Health Issues Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Modified amine lipids Sep. 03, 2024
-
Patent Title: Compositions and methods for ttr gene editing and treating attr amyloidosis Apr. 23, 2024
-
Patent Title: Compositions and methods for ttr gene editing and treating attr amyloidosis Oct. 24, 2023
-
Patent Title: Polynucleotides, compositions, and methods for genome editing Jul. 11, 2023
-
Patent Title: Stabilized nucleic acids encoding messenger ribonucleic acid (mrna) Jun. 13, 2023
-
Patent Title: Compositions and methods for treating alpha-1 antitrypsin deficiency Jan. 10, 2023
-
Patent Title: Modified guide rnas Oct. 25, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of NTLA in WallStreetBets Daily Discussion
Recent insights relating to NTLA
Recent picks made for NTLA stock on CNBC
ETFs with the largest estimated holdings in NTLA
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NTLA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.